NCT00944658View on ClinicalTrials.gov

Spondylitis Trial of Apremilast for Better Rheumatic Therapy

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions
Ankylosing Spondylitis
Interventions
DRUG

Apremilast

10mg twice a day, dose was titrated by 20mg every 2 days until the maximum dose 30mg twice a day for 12weeks

DRUG

Placebo (sugar pill)

twice a day

Trial Locations (1)

W6 8RF

The Kennedy Institute Clinical Trials Unit, 4 West, Charing Cross Hospital, London

Sponsors

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

Imperial College London

OTHER